Skip to content

Plain-English explainer

Stopping Semaglutide Before Surgery & Anesthesia

Explained by Sofia Mendez, Patient Education Editor

We keep this plain-English — no jargon, every claim sourced.

If you take semaglutide (Wegovy, Ozempic, or Rybelsus) and you have surgery, an endoscopy, or any procedure with sedation coming up, this is a real safety question worth getting right. The advice has shifted recently — from "stop it for everyone" toward a more individualized, risk-based approach — so here is what current guidance actually says and why it changed. This is high-stakes, so the single most important step is simple: tell your surgical and anesthesia team you are on semaglutide.

Why semaglutide matters for anesthesia at all

The concern is mechanical, not mysterious. Semaglutide works in part by slowing how fast the stomach empties — the same effect behind its common gastrointestinal side effects. Under anesthesia, your protective airway reflexes are suppressed, so if the stomach still holds food or fluid, there is a risk it can come up and be breathed into the lungs. That event, pulmonary aspiration, is uncommon but serious, and avoiding it is why anesthesiologists care whether your stomach is truly empty before sedation.

The signal that this is a genuine concern came from clinical observation: studies and a scoping review found that some people on GLP-1 drugs had retained stomach contents even after following standard fasting instructions1. Endoscopy data backed this up — systematic review and meta-analysis found GLP-1 users were more likely to have residual gastric contents and, in some series, interrupted or repeat procedures2. So the worry is evidence-based, not theoretical.

Quick answer

The advice has shifted: from blanket holds to individualized risk

When the aspiration signal first emerged, the initial reaction was cautious and broad — guidance leaned toward holding GLP-1 drugs before procedures. More recent, multisociety guidance has refined that stance. Rather than a one-size-fits-all stop, expert societies now favor an individualized, risk-stratified approach: weigh how high-risk the patient is for a full stomach against the downsides of interrupting a drug that may be treating diabetes or obesity3.

In practice, that newer framing means the decision considers things like whether you are having active GI symptoms (nausea, vomiting, bloating, feeling full), what dose you are on and whether you recently increased it, and what kind of procedure and anesthesia is planned — instead of automatically stopping the drug for everyone3. The point of the shift is to avoid both extremes: neither ignoring a real aspiration risk nor needlessly destabilizing someone's glucose or treatment by stopping the medicine when it may not be necessary.

Here's how it's decided
Current guidance weighs these together rather than applying one fixed rule.

What about the "hold it for about a week" advice?

You may have heard a specific number — often around a week — for holding the weekly injection before surgery. That kind of interval reflects how long-acting injectable semaglutide is: it is dosed weekly precisely because it lingers, so a hold long enough to matter is measured in days, not hours. Research has directly examined how different interruption intervals affect what is left in the stomach: a study using upper-endoscopy assessment looked at various perioperative semaglutide interruption intervals and their effect on residual gastric content, informing how long a meaningful hold needs to be4.

But — and this is the key update — current guidance treats any such interval as a starting point for an individualized decision, not an unbreakable rule, and emphasizes that the anesthesia team can also assess your stomach on the day. Point-of-care gastric ultrasound, for example, lets clinicians actually check whether your stomach is empty before proceeding, which can refine or override a fixed time-based hold5. The takeaway: the exact timing is a clinical judgment your care team makes, factoring in your drug, dose, symptoms, and the procedure — not a number to apply on your own.

Do NOT stop semaglutide on your own

This is the part that matters most for you as a patient: do not decide to start or stop semaglutide before a procedure by yourself. Two reasons. First, if you stop and your team would actually have preferred you continue (or simply treat you as "full stomach" and adjust their technique), you may have interrupted treatment for nothing. Second, and more important, stopping abruptly can matter for glucose control if you have diabetes, and the right plan depends on details only your prescriber and anesthesia team can weigh together. Because semaglutide is also long-acting, stopping a few days early does not fully clear it anyway, which is exactly why the team plans around it3. Tell every relevant clinician — surgeon, anesthesiologist, proceduralist — that you take semaglutide, and let them direct the plan.

A note on the days around your procedure

If your team does ask you to hold the drug, the practical reality is that one missed weekly dose is generally low-stakes for weight management, given how long semaglutide stays active — losing the appetite effect for a week is not the same as stopping the drug, which is what drives the weight regain seen after truly stopping semaglutide. For people using it for type 2 diabetes, though, your clinician may need to bridge your blood-sugar management around the hold. And remember that the underlying reason for all this — delayed gastric emptying — is the same mechanism behind everyday symptoms like Ozempic burps and reflux; if you have been having a lot of those, that is exactly the kind of "active GI symptom" worth flagging to your anesthesia team, since it suggests your stomach may be slower to empty.

The bottom line

Should you stop semaglutide before surgery? Increasingly, the answer is "it depends — and your care team decides." The concern is real: semaglutide slows gastric emptying, and GLP-1 users can have retained stomach contents that raise aspiration risk under anesthesia12. But newer multisociety guidance has moved away from a blanket hold toward individualized, risk-based decisions that weigh your symptoms, dose, and procedure3, sometimes aided by on-the-day stomach checks5. The one rule that applies to everyone: disclose that you take semaglutide and let your surgical and anesthesia team set the plan — do not stop it on your own. For the full evidence picture on the medication, see our pillar guide, Semaglutide: How It Works, Results & Side Effects; to compare prescribers, see our guide to the best semaglutide options.

A few more quick ones

Do I have to stop semaglutide before surgery?

Not automatically. Newer multisociety guidance favors an individualized, risk-based decision rather than a blanket hold — weighing your GI symptoms, dose, and the procedure. The essential step is to tell your surgical and anesthesia team you take semaglutide and let them set the plan. Do not stop it on your own.

Why does semaglutide matter for anesthesia?

It slows how fast the stomach empties. Under anesthesia your airway reflexes are suppressed, so retained stomach contents can be breathed into the lungs (aspiration), which is uncommon but serious. Studies show GLP-1 users can have retained gastric contents even after standard fasting, which is why teams ask about it.

How long before surgery should semaglutide be held?

Because injectable semaglutide is long-acting, any meaningful hold is measured in days — you may have heard around a week — but current guidance treats that as a starting point for an individualized decision, not a fixed rule. Anesthesia teams may also use gastric ultrasound to check your stomach on the day. Follow your team's specific instructions.

Is it safe to skip a dose of semaglutide for a procedure?

For weight management, missing one weekly dose is generally low-stakes because the drug stays active for a while. If you have type 2 diabetes, your clinician may need to manage your blood sugar around the hold. Either way, let your prescriber and anesthesia team coordinate the plan rather than deciding alone.

Where this comes from

Every claim above traces back to one of these — real studies and official labeling.

  1. Chang MG, Ripoll JG, Lopez E, et al. (2024). A Scoping Review of GLP-1 Receptor Agonists: Are They Associated with Increased Gastric Contents, Regurgitation, and Aspiration Events?. Journal of Clinical Medicine. https://pubmed.ncbi.nlm.nih.gov/39518474/
  2. Abdulraheem A, Abujaber B, Ayers L, et al. (2025). Impact of GLP-1 receptor agonists on upper gastrointestinal endoscopy: an updated systematic review and meta-analysis.. Surgical Endoscopy. https://pubmed.ncbi.nlm.nih.gov/40634731/
  3. Kindel TL, Wang AY, Wadhwa A, et al. (2025). Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period.. Clinical Gastroenterology and Hepatology. https://pubmed.ncbi.nlm.nih.gov/39480373/
  4. Santos LB, Mizubuti GB, da Silva LM, et al. (2024). Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy.. Journal of Clinical Anesthesia. https://pubmed.ncbi.nlm.nih.gov/39476514/
  5. Haskins SC, Bronshteyn YS, Ledbetter L, et al. (2025). ASRA pain medicine narrative review and expert practice recommendations for gastric point-of-care ultrasound to assess aspiration risk.. Regional Anesthesia & Pain Medicine. https://pubmed.ncbi.nlm.nih.gov/40250977/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Keep exploring